As SIKs are known to inhibit type IIa HDACs and able to restore MEF2-mediated transcription, it has been proposed that maneuvers that upregulate SIK activity could offer new opportunity to explore disease-modifying strategy for PAH (António et al., 2022). Here, SIK1 is linked to pulmonary arterial hypertension.